<DOC>
	<DOCNO>NCT00466531</DOCNO>
	<brief_summary>RATIONALE : Using T cell patient treat laboratory may help body build effective immune response kill cancer cell . Drugs use chemotherapy , cyclophosphamide , work different way stop growth cancer cell , either kill cell stop divide . Giving laboratory-treated T cell together cyclophosphamide may kill cancer cell . PURPOSE : This two-stage protocol , consist single-institution phase I safety study multi-institution phase IIa extension study .</brief_summary>
	<brief_title>Treatment Relapsed Chemotherapy Refractory Chronic Lymphocytic Leukemia Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted B Cell Specific Antigen CD19</brief_title>
	<detailed_description>OBJECTIVES : Phase 1 : The primary objective ass safety autologous T cell genetically modify express chimeric antigen receptor ( CAR ) target CD19 antigen ( 19-28z ) without condition chemotherapy . • Phase IIa : The primary objective compare relative engraftment persistence two CAR modify CD19-targeted T cell express different co-stimulatory signal domain CD28 ( 19-28z ) 4-1BB ( CART-19 : CD3z-4-1BB ) CAR construct . To compare vivo survival genetically modify 19-28z CAR+ T cell T cell infusion alone combination condition chemotherapy . - To compare gene transfer/expression efficiency two viral vector ( retrovirus vs. lentivirus ) . - To assess anti-leukemic activity adoptively transfer CD19-targeted modify T cell link CD28 ( 19-28z ) 4-1BB signaling domain ( CART-19 : CD3z-4-1BB ) . OUTLINE : The first stage standard 3-step phase I dose escalation trial ass safety 19-28z CAR express autologous T cell without prior conditioning chemotherapy . In Step 1 , cohort patient receive low plan dose 19-28z+ modify T cell . In Step 2 , cohort patient receive cyclophosphamide conditioning chemotherapy follow low plan dose 19-28z+ modify T cell . If less 33 % patient cohort ( Step 2 ) experience unanticipated dose-limiting toxicity . In Step 3 , cohort patient treat investigator 's choice conditioning chemotherapy follow high dose 19-28z+ modify T cell . If less 33 % patient initial cohort ( Step 3 ) experience unanticipated dose-limiting toxicity , cohort Step 3 may expand include 15 patient . In Step 3 , additional cohort Waldenstrom 's Macroglobulinemia ( WM ) patient treat investigator 's choice conditioning chemotherapy follow 19-28z+ T cell . However , maximize safety WM patient , treat low dose modify T cell ( 1x106 19-28z+ T cells/kg ) . If toxicity observe initial cohort , dose may increase standard 3-step dose-escalation scheme describe . In Phase IIa extension part trial , 12 patient MSKCC enrol , treat co-infusion 19-28z CART-19 : CD3z-4-1BB+ modified T cell mixed 1:1 ratio MTD T cell determine phase I trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Inclusion : • Patients must follow CD19+ B cell leukemia lymphoma either relapse chemotherapyrefractory disease evidence residual disease follow therapy . In case , patient 's disease must confirm MSKCC . CLL : Patients must diagnosis CLL evidence flow cytometry , bone marrow histology , and/or cytogenetics . Other low grade Bcell neoplasms eligible study , small lymphocytic lymphoma ( SLL ) , follicular lymphoma , Waldenstrom 's macroglobulinemia , hairy cell leukemia , marginal zone lymphoma , mantle cell lymphoma . Creatinine ≤2.0 mg/100 ml , bilirubin ≤2.0 mg/100 ml , AST ALT ≤3.0x normal , PT PTT ≤ 2x normal outside set stable chronic anticoagulation therapy , granulocytes ≥1,000/mm3 , platelets ≥50,000/mm3 , hemoglobin ≥8.0g/dl transfusion support Adequate cardiac function ( LVEF ≥40 % ) assess ECHO MUGA scan perform within 1 month treatment . Adequate pulmonary function assess ≥92 % oxygen saturation room air pulse oximetry . Life expectancy &gt; 3 month . Exclusion : Karnofsky performance status &lt; 70 . CLL patient active transformed disease ( Richter 's transformation ) ineligible enrollment study . Patients follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Myocardial infarction ≤6 month prior enrollment History clinically significant ventricular arrhythmia unexplained syncope , believe vasovagal nature due dehydration History severe nonischemic cardiomyopathy EF ≤20 % Patients HIV , hepatitis B hepatitis C infection ineligible . Patients concurrent active malignancy define malignancy require therapy expectant observation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>06-138</keyword>
</DOC>